TG Therapeutics, Inc. – TGTX

TG Therapeutics – Innovating tomorrow’s therapy today

What does TGTX do?

TG Therapeutics’ primary business involves the development of therapies for B-cell malignancies and autoimmune diseases. The company’s lead product candidates include ublituximab, a glycoengineered anti-CD20 monoclonal antibody, and umbralisib, an oral, once-daily inhibitor of PI3K-delta and CK1-epsilon. These therapies are aimed at treating conditions such as chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and multiple sclerosis (MS). TG Therapeutics also focuses on combination therapies to enhance treatment efficacy and patient outcomes

Competitors

These competitors share similarities with TGTX in terms of their focus on oncology and autoimmune diseases, particularly B-cell malignancies. However, they differ in terms of company size, market presence, financial resources, and the breadth of their product portfolios. TGTX, being a smaller and more specialized company, focuses on innovative therapies within its niche, while its larger competitors have more diversified operations and greater resources to support their research and development efforts.

5 year stock performance, deepest trough and highest peak

TG Therapeutics has shown notable resilience and growth in its stock performance over the past five years. The company’s focus on innovative therapies for B-cell malignancies and autoimmune diseases, along with strategic partnerships and a commitment to scientific excellence, has contributed to its strong market position. Let’s delve into the key aspects of TGTX’s stock performance.

Deepest trough

One of the critical metrics in analyzing stock performance is identifying the lowest points or troughs. For TGTX, the deepest trough occurred during a period of market volatility and heightened regulatory scrutiny. Despite these challenges, TG Therapeutics managed to navigate through the downturn, thanks to its robust pipeline and strategic initiatives. The company’s focus on advancing its clinical trials and securing funding played a crucial role in mitigating the impact of the market downturn.

Highest peak

On the flip side, TGTX has also experienced significant highs in its stock performance. The highest peak in the past five years can be attributed to several factors, including successful clinical trial results, regulatory approvals, and positive market sentiment. TG Therapeutics’ ability to consistently advance its pipeline and secure strategic partnerships has further bolstered investor confidence. The company’s strategic focus on developing innovative therapies and expanding its market presence has contributed to its impressive stock performance.

Growth

G Therapeutics has demonstrated impressive growth over various time periods, as evidenced by its compounded annual growth rate (CAGR). Over the past three years, the CAGR stands at an astounding +1054.11%, while the five-year CAGR is +333.86%. Over eight years, the CAGR is +150.13%, and over ten years, it is +108.23%. Looking ahead, the average estimated CAGR for the coming three years is +47.24%.

These figures highlight the company’s robust revenue growth, driven by its innovative therapies and strategic initiatives. Despite fluctuations in year-over-year growth, TG Therapeutics has maintained strong double-digit growth rates, reflecting its ability to navigate market challenges and capitalize on opportunities.

The high CAGR over the past three and five years indicates rapid expansion, likely fueled by successful clinical trials, regulatory approvals, and strategic partnerships. The estimated growth rate for the coming three years, while lower than historical rates, still suggests significant potential for continued revenue growth as the company advances its pipeline and expands its market presence.

Institutional Ownership

Over the past few months, there has been a slight but noticeable increase in the institutional ownership of TG Therapeutics’ stock. This trend suggests that institutional investors are gaining confidence in the company’s strategic direction, innovative pipeline, and potential for future growth. The rising institutional ownership can be attributed to several factors:

Positive Clinical Trial Results

Successful outcomes from clinical trials and advancements in TG Therapeutics’ pipeline have likely contributed to increased investor confidence. Positive data and regulatory milestones can attract institutional investors looking for promising opportunities in the biopharmaceutical sector.

Strategic Partnerships and Collaborations

TG Therapeutics’ ability to form strategic partnerships and collaborations with other biopharmaceutical companies, academic institutions, and research organizations enhances its research and development capabilities. These partnerships can provide additional resources and expertise, making the company more attractive to institutional investors.

Financial Performance

Strong financial performance, including revenue growth and effective management of financial resources, can also drive institutional interest. Investors are likely to be encouraged by the company’s ability to secure funding, manage its operations efficiently, and achieve its strategic goals.

Market Position and Competitive Advantage

TG Therapeutics’ focus on innovative therapies for B-cell malignancies and autoimmune diseases, along with its deep understanding of B-cell biology, positions the company as a leader in its niche. Institutional investors may view this competitive advantage as a key factor in the company’s long-term success.

The slight increase in institutional ownership reflects growing confidence in TG Therapeutics’ potential to deliver value to its shareholders. As the company continues to advance its pipeline, secure regulatory approvals, and expand its market presence, institutional interest is likely to remain strong, further supporting the company’s stock performance and overall growth prospects.

Conclusion

In my honest opinion, with the latest results of TGTX’s MS study, TGTX is bound for an upside explosion in its stock price. However, with a monthly standard deviation of almost 40%, volatility in the stock’s price is a fact and something you should be wary of. This results in an exposure of only 2.5%. Usually, stocks have around 10% of monthly standard deviation. While holding on to risking 1% of capital, a 10% exposure is great. Since the standard deviation of TGTX is four times as much, my exposure will be divided by four for a starter position.

With January close, TGTX’s earnings report behind us and its technicals being in favor of the stock, I am willing to risk a portion to catch a big upside profit potential.